GLAXOSMITHKLINE PHARMACEUTICALS
Back to Cashflow Statement
|
GLAXOSMITHKLINE PHARMACEUTICALS Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹-737 Cr | ₹-769 Cr | ₹-561 Cr | ₹-1,543 Cr | ₹-524 Cr |
What is the latest Cash Flow from Financing Activities ratio of GLAXOSMITHKLINE PHARMACEUTICALS ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2026 | ₹-737 Cr |
| Mar2025 | ₹-769 Cr |
| Mar2024 | ₹-561 Cr |
| Mar2023 | ₹-1,543 Cr |
| Mar2022 | ₹-524 Cr |
How is Cash Flow from Financing Activities of GLAXOSMITHKLINE PHARMACEUTICALS Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹-737 Cr | Negative | |
| Mar2025 | ₹-769 Cr | Negative | |
| Mar2024 | ₹-561 Cr | Negative | |
| Mar2023 | ₹-1,543 Cr | Negative | |
| Mar2022 | ₹-524 Cr | - | |
Compare Cash Flow from Financing Activities of peers of GLAXOSMITHKLINE PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAXOSMITHKLINE PHARMACEUTICALS | ₹45,921.8 Cr | 7% | 6.7% | -4.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹457,073.0 Cr | 7.3% | 8.4% | 13.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹307,147.0 Cr | 15.3% | 24.1% | 63% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹181,626.0 Cr | 1% | 2.5% | 33.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹115,685.0 Cr | 1% | 15.9% | 14% | Stock Analytics | |
| CIPLA | ₹113,589.0 Cr | 0.4% | 7.9% | -6.2% | Stock Analytics | |
GLAXOSMITHKLINE PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAXOSMITHKLINE PHARMACEUTICALS | 7% |
6.7% |
-4.6% |
| SENSEX | 5.5% |
13.3% |
-3.4% |
You may also like the below Video Courses